Aug 25 (Reuters) - The National Institutes of Health has initiated a late-stage study to test plasma-derived COVID-19 therapies including Emergent BioSolutions Inc's candidate as a potential outpatient treatment for those at high risk of progression to severe disease, the drug developer said on Wednesday. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)
Stock Market News in real time
- Stock Market
- Stock Market News in real time
- Economy
- Emergent's COVID-19 therapy to be tested in NIH-sponsored study